Initial areas of interest will be CNS and cardiovascular disorders.

Lipomics Technologies and Duke University signed a deal to identify pharmacometabolomic markers in various clinical areas. Initial research will focus on CNS disorders such as schizophrenia and depression and cardiovascular diseases in terms of response to statins.

Under this two-year agreement, Lipomics will provide Duke technology and services for biomarker research, validation, and analysis. In return, Lipomics has the option to license diagnostic rights on all such markers developed.

Lipomics’ platform and technologies relating to lipid profiles and data transfer and interpretation services will be used by the Duke scientists.

Previous articleRosetta Genomics Taps Columbia University to Advance its Cancer Diagnostics Program
Next articleAMRI Acquires Manufacturing Facilities in India for $11M